Our cover story this month is on the next wave of immune-based therapies for patients with immune-mediated inflammatory conditions — and the prospects are bright.
I want to thank our faculty — Massimo Gadina, PhD, Jane Salmon, MD, Vibeke Strand, FACP, MACR, and Grace C. Wright, MD, PhD — and focus my comments on one aspect of this influx, namely the rise of immunomodulation. Our history of immune-based therapies dates back a mere 75 years or so, with the discovery and development of glucocorticoids. As we all know, the miracle-cure prospects for glucocorticoids were quickly
